Targeted delivery of epirubicin to breast cancer cells using poly-aptamer DNA nanocarriers prepared by the RCA method with multiple repeats of aptamers of FOXM1 and AS1411
Sign Up to like & getrecommendations! Published in 2023 at "Drug Development and Industrial Pharmacy"
DOI: 10.1080/03639045.2023.2199075
Abstract: Abstract Objective We evaluated the DNA nanocarriers synthesized by rolling circle amplification (RCA), composed of multiple repeats of AS1411 and FOXM1 aptamers for targeted epirubicin delivery to breast cancer cells. Methods Agarose gel electrophoresis and… read more here.
Keywords: cancer cells; epirubicin; dna nanocarriers; breast cancer ... See more keywords
Preventing effect of astragalus polysaccharide on cardiotoxicity induced by chemotherapy of epirubicin: A pilot study
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030000
Abstract: To assess the clinical effect of astragalus polysaccharide in preventing cardiotoxicity induced by chemotherapy of epirubicin. Two hundred forty-eight patients with breast cancer or malignant lymphoma were randomly divided into the experimental group (EG) (n… read more here.
Keywords: chemotherapy epirubicin; astragalus polysaccharide; epirubicin; cardiotoxicity ... See more keywords
Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy
Sign Up to like & getrecommendations! Published in 2018 at "Veterinary and Comparative Oncology"
DOI: 10.1111/vco.12329
Abstract: The aims of this study were to report treatment outcomes for dogs with histiocytic sarcoma (HS) treated with both lomustine and epirubicin, and to report response rates to epirubicin as a rescue therapy in dogs… read more here.
Keywords: treatment; histiocytic sarcoma; dogs treated; epirubicin ... See more keywords
Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial
Sign Up to like & getrecommendations! Published in 2024 at "BMJ Open"
DOI: 10.1136/bmjopen-2023-075158
Abstract: Introduction Sepsis remains the major cause of death among hospitalised patients in intensive care. While targeting sepsis-causing pathogens with source control or antimicrobials has had a dramatic impact on morbidity and mortality of sepsis patients,… read more here.
Keywords: trial; placebo; study; phase ... See more keywords
Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.11501
Abstract: 11501 Background: Anthracycline-based chemotherapy has been the standard first-line treatment for advanced STS for decades. The phase 3 ANNOUNCE trial failed to demonstrate an overall survival (OS) benefit with olaratumab plus doxorubicin compared to doxorubicin.… read more here.
Keywords: week; treatment; maintenance; first line ... See more keywords
Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0185625
Abstract: HuR (ELAVL1), a RNA-binding protein, plays a key role in posttranscriptional regulation of multidrug resistance (MDR)-related genes. Among various HuR-regulated oncogenic transcripts, the activation of galectin-3/β-catenin survival pathway is critical to induce transcription of cyclin… read more here.
Keywords: epirubicin; hur; multidrug resistance; cancer cells ... See more keywords
Study of epirubicin sustained–release chemoablation in tumor suppression and tumor microenvironment remodeling
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1064047
Abstract: Introduction Although intratumoral chemoablation can obtain an impressive therapeutic effect, there is still incomplete ablation and tumor recurrence in some patients. This could be due to the short retention time of the drug in the… read more here.
Keywords: injection; epirubicin; tumor; tumor microenvironment ... See more keywords